Literature DB >> 7513255

Cytotoxic T-lymphocyte response to autologous human squamous cell cancer of the lung: epitope reconstitution with peptides extracted from HLA-Aw68.

C L Slingluff1, A L Cox, J M Stover, M M Moore, D F Hunt, V H Engelhard.   

Abstract

Cytotoxic T-lymphocytes (CTLs) specific for autologous human squamous cell cancer of the lung were generated by stimulation of peripheral blood lymphocytes with autologous tumor cells in vitro. The CTL line was >97% CD3+, CD8+, CD16- and produced tumor necrosis factor-alpha, gamma-interferon, and granulocyte-macrophage colony-stimulating factor after stimulation with autologous tumor. The CTLs lysed autologous tumor but failed to recognize autologous or histocompatibility leukocyte antigen-matched lymphoid cells, K562, or allogeneic tumor cells of several histological types. Antibody-blocking studies suggested that the CTLs recognized one or more antigens presented by the class I major histocompatibility complex molecule Aw68. To characterize these antigens further, histocompatibility leukocyte antigen Aw68 molecules were extracted from the squamous cell cancer of the lung tumor line by immunoaffinity chromatography, and the associated peptides were eluted in acid and separated by reversed-phase high-performance liquid chromatography. Reconstitution of the CTL epitope was evaluated by adding these peptides to autologous Epstein-Barr virus-transformed B-cells. Two peaks of reconstituting activity were observed, suggesting that these CTLs recognize at least two Aw68-associated peptides. This study confirms the existence of a CTL response against autologous human squamous cell cancer of the lung and suggests that this CTL response is directed against peptide epitopes presented by the class I major histocompatibility complex molecules. It is anticipated that this approach will permit identification of peptide epitopes for lung cancer-specific CTLs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7513255

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  17 in total

1.  Growth stimulation of tumor-specific cytotoxic T lymphocytes on concanavalin a-immobilized carrier beads.

Authors:  S Q Liu; L S Liu; T Ohno
Journal:  Cytotechnology       Date:  1998-01       Impact factor: 2.058

2.  Induction of auto-logous human cytotoxic T lymphocytes (CTL) from peripheral blood against tumor cells.

Authors:  T Ohno
Journal:  Cytotechnology       Date:  1997-01       Impact factor: 2.058

Review 3.  Direct identification of tumor-associated peptide antigens.

Authors:  V H Engelhard
Journal:  Springer Semin Immunopathol       Date:  1996

4.  Analysis of the CD8+ T cell anti-HIV activity in heterologous cell co-cultures reveals the benefit of multiple HLA class I matches.

Authors:  M Scott Killian; Fernando Teque; Ramu Sudhagoni
Journal:  Immunogenetics       Date:  2017-07-22       Impact factor: 2.846

5.  Targeted tumor cell death induced by autologous tumor-specific T lymphocyte recognition of wild-type p53-derived peptides.

Authors:  Hideo Tsurushima; Yoshihiko Yoshii; Kam W Leong; Tadao Ohno
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

6.  Activation by interferon-gamma of expression of ICAM-1 and MHC class II antigens in tumour cells from colorectal carcinomas.

Authors:  I Donnellan; J Cantrill; I Fraser; A Morris
Journal:  Clin Mol Pathol       Date:  1995-02

7.  Cytotoxic T lymphocytes directed against a tumor-specific mutated antigen display similar HLA tetramer binding but distinct functional avidity and tissue distribution.

Authors:  Hamid Echchakir; Guillaume Dorothée; Isabelle Vergnon; Jeanne Menez; Salem Chouaib; Fathia Mami-Chouaib
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-01       Impact factor: 11.205

8.  Shared immunoproteome for ovarian cancer diagnostics and immunotherapy: potential theranostic approach to cancer.

Authors:  Ramila Philip; Sidhartha Murthy; Jonathan Krakover; Gomathinayagam Sinnathamby; Jennifer Zerfass; Lorraine Keller; Mohan Philip
Journal:  J Proteome Res       Date:  2007-06-05       Impact factor: 4.466

9.  Phosphorylated peptides are naturally processed and presented by major histocompatibility complex class I molecules in vivo.

Authors:  A L Zarling; S B Ficarro; F M White; J Shabanowitz; D F Hunt; V H Engelhard
Journal:  J Exp Med       Date:  2000-12-18       Impact factor: 14.307

Review 10.  Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.

Authors:  Aurélie Durgeau; Yasemin Virk; Stéphanie Corgnac; Fathia Mami-Chouaib
Journal:  Front Immunol       Date:  2018-01-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.